CFLAR and neoplasm: Bortezomib enhanced the effectiveness of TRAIL by upregulating TRAIL-R2 expression on the tumor cell surface, enhancing TRAIL death-inducing signaling complex (DISC) formation, downregulating the antiapoptotic protein cFLIPL, and increasing the caspase-8/cFLIP ratio, thereby facilitating the activation of the apoptotic cascade [52].